Implied Volatility Surging for XOMA Royalty Stock Options

Options traders are pricing in a large move for XOMA Royalty (XOMA), with the March 20, 2026 $35 call showing among the highest implied volatility on the tape. Fundamentals are weak: Zacks assigns a #5 (Strong Sell) rank in the Medical - Biomedical & Genetics sector, and over the past 60 days three analysts cut current-quarter estimates (none raised), dragging the Zacks consensus from earnings of $0.06 to a loss of $0.04 per share. The elevated IV may create tactical opportunities (e.g., premium selling), but the deteriorating analyst outlook and strong negative ranking signal heightened downside risk for equity holders.

Analysis

Market structure: The isolated spike in implied volatility on XOMA (Mar 20, 2026 $35 call) signals concentrated option demand and a market pricing of a >=30-50% directional move by that expiry rather than broad sector stress. Winners in the short run are volatility sellers and desks that can delta-hedge; losers are leverage/long-equity holders if a binary adverse event occurs. Cross-asset impact is limited but a realized large move would raise funding costs for small-cap biotech, tighten credit spreads for high-beta healthcare names, and briefly lift correlation with small-cap equity volatility indices (e.g., VXN/XVZ equivalents).

Key Decisions for Investors

• If IV percentile >80 and no confirmed binary within 60 days: establish a defined-risk short-vol trade — sell Mar‑20‑2026 XOMA $35/$50 call spread sized to 1–2% portfolio risk (max loss capped). Close if IV falls >30% or stock gaps >30% intra-session.
• If credible binary catalyst is announced within 90–180 days (8‑K, royalty settlement, trial readout): buy a Mar‑2026 straddle or buy the $35 call (allocate 0.5–1% portfolio); target 100–200% return or exit 3 days post-catalyst; cut losses at 50% premium decay.
• Establish a relative-value pair: short 1–2% notional XOMA (or buy 6–9 month put spread) and go long 1% HIMS (or a large-cap healthcare ETF) to capture idiosyncratic downside while remaining long sector exposure; review after 3 months.
• Set automated monitors for 30–120 days: trigger alerts on (a) any XOMA 8‑K/10‑Q/insider transactions, (b) analyst estimate revisions beyond ±$0.02 EPS, or (c) IV move ±25% — act within 48 hours of trigger with predefined size and stop rules.